Improving opportunities for effective management of gastro-oesophageal reflux disease.
The recent introduction of proton pump inhibitors has extraordinarily improved the therapeutic approach to gastro-oesophageal reflux disease. The concept of decreasing gastric acid secretion and increasing the pH in the lower oesophagus has been demonstrated to be therapeutically effective and the higher the level of pH achieved, the better the results. In spite of the evident efficacy of these molecules, there are still many patients who will continue to have symptoms despite medical treatment. Proton pump inhibitors suppress gastric acidity, but this effect shows a remarkable interindividual variation depending on different reasons. Thus, it is still possible to optimise medical therapy for gastro-oesophageal reflux disease. Esomeprazole, the S-isomer of omeprazole, has an advantageous metabolism and this particular feature translates into superior clinical efficacy. Clinical trials for initial and long-term treatment across the gastro-oesophageal reflux disease spectrum, have clearly demonstrated the superiority of esomeprazole over omeprazole, even if tolerability and safety are very similar.
Vigneri
S
S
Department of Internal Medicine, University of Palermo, Italy. pvigner@tin.it
Tonini
M
M
Scarpignato
C
C
Savarino
V
V
D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001682:Biological Availability; D064098:Esomeprazole; D004941:Esophagitis / Q000188:drug therapy; D005753:Gastric Mucosa / Q000473:pathology; D005764:Gastroesophageal Reflux; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007536:Isomerism; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D009853:Omeprazole; D064098:Esomeprazole